Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eliza Slawther

Senior Writer

London, UK

Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.

Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.

Latest From Eliza Slawther

How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.

BioPharmaceutical Cancer

Preparing For The Next Pandemic: Experts Talk AI Vaccines, Regulatory Acceptance & Earlier Human Trials

AI-generated vaccines, fast-moving regulatory systems and scalable manufacturing platforms will be key in preparing for future pandemics, according to vaccine and immunology experts including the CEOs of CEPI and Gavi.

BioPharmaceutical International

Final Funding Blow For J&J’s Spravato In England, Despite Reimbursement In 26 Other Countries

J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.

BioPharmaceutical Neurology

Switzerland Adopts Changes To Human Research & Clinical Trial Regulations

Updated clinical trial reporting rules and stronger participant protections are among the several changes to research in Switzerland that will apply from November, while new regulations on clinical trial transparency will apply from March 2025.

Europe Switzerland

Pharmacogenomics Could Reduce Annual £2bn Cost Of Adverse Drug Reactions In UK

With more than 16% of hospital admissions in the UK caused by adverse drug reactions, costing the country upwards of £2bn a year, a genomics expert explains how pharmacogenomic tests could benefit both patients and the health care system.

BioPharmaceutical Drug Safety

How Accumulus’s ‘Dossier In The Cloud’ Platform Is Modernizing ‘Inefficient’ Drug Regulation

Global non-profit Accumulus Synergy wants to remove “unnecessary complexities and inefficiencies” in the regulatory process with its cloud-based communication platform, the corporation’s CEO and chief regulatory innovation officer tell the Pink Sheet.

BioPharmaceutical Europe
See All